[Jul 03, 2025] CIC PDF Questions and Testing Engine With 174 Questions [Q31-Q50]

Rate this post

[Jul 03, 2025] CIC PDF Questions and Testing Engine With 174 Questions

Updated Exam Engine for CIC Exam Free Demo & 365 Day Updates

QUESTION 31
As part of their antimicrobial stewardship initiative, Hospital A is using a qualitative study to assess their program. What type of data will be collected using this approach?

Numeric

Reliable

Reproducible

Subjective

QUESTION 32
When assessing a patient’s infection prevention and control educational needs, it is necessary to FIRST determine the patient’s

severity of illness.

educational background.

duration of hospitalization.

baseline knowledge of the subject.

The correct answer is D, “baseline knowledge of the subject,” as this is the necessary first step when assessing a patient’s infection prevention and control educational needs. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, effective patient education in infection prevention and control requires a tailored approach that begins with understanding the patient’s existing knowledge and comprehension of the topic. Determining baseline knowledge allows the infection preventionist (IP) to identify gaps, customize educational content to the patient’s level of understanding, and ensure the information is relevant and actionable (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.1 – Develop and implement educational programs). This step ensures that education is neither too basic nor overly complex, maximizing its effectiveness in promoting behaviors such as hand hygiene, wound care, or adherence to isolation protocols.
Option A (severity of illness) is an important clinical consideration that may influence the timing or method of education delivery, but it is not the first step in assessing educational needs. The severity might affect the patient’s ability to learn, but it does not directly inform the content or starting point of the education. Option B (educational background) provides context about the patient’s general learning capacity (e.g., literacy level or language preference), but it is secondary to assessing specific knowledge about infection prevention, as background alone does not reveal current understanding. Option C (duration of hospitalization) may impact the opportunity for education but is not a primary factor in determining what the patient needs to learn; it is more relevant to scheduling or prioritizing educational interventions.
The focus on baseline knowledge aligns with adult learning principles endorsed by CBIC, which emphasize assessing learners’ prior knowledge to build effective educational strategies (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.2 – Evaluate the effectiveness of educational programs).
This approach ensures patient-centered care and supports infection control by empowering patients with the knowledge to participate in their own prevention efforts.
References: CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competencies 4.1 – Develop and implement educational programs, 4.2 – Evaluate the effectiveness of educational programs.

QUESTION 33
Which humoral antibody indicates previous infection and assists in protecting tissue?

IgA

IgD

IgG

IgM

Humoral antibodies, or immunoglobulins, play distinct roles in the immune system, and their presence or levels can provide insights into infection history and ongoing immune protection. The Certification Board of Infection Control and Epidemiology (CBIC) recognizes the importance of understanding immunological responses in the “Identification of Infectious Disease Processes” domain, which is critical for infection preventionists to interpret diagnostic data and guide patient care. The question focuses on identifying the antibody that indicates a previous infection and assists in protecting tissue, requiring an evaluation of the functions and kinetics of the five major immunoglobulin classes (IgA, IgD, IgG, IgM, IgE).
Option C, IgG, is the correct answer. IgG is the most abundant antibody in serum, accounting for approximately 75-80% of total immunoglobulins, and is the primary antibody involved in long-term immunity. It appears in significant levels after an initial infection, typically rising during the convalescent phase (weeks to months after exposure) and persisting for years, serving as a marker of previous infection.
IgG provides protection by neutralizing pathogens, opsonizing them for phagocytosis, and activating the complement system, which helps protect tissues from further damage. The Centers for Disease Control and Prevention (CDC) and clinical immunology references, such as the “Manual of Clinical Microbiology” (ASM Press), note that IgG seroconversion or elevated IgG titers are commonly used to diagnose past infections (e.
g., measles, hepatitis) and indicate lasting immunity. Its ability to cross the placenta also aids in protecting fetal tissues, reinforcing its protective role.
Option A, IgA, is primarily found in mucosal secretions (e.g., saliva, tears, breast milk) and plays a key role in mucosal immunity, preventing pathogen adhesion to epithelial surfaces. While IgA can indicate previous mucosal infections and offers localized tissue protection, it is not the primary systemic marker of past infection or long-term tissue protection, making it less fitting. Option B, IgD, is present in low concentrations and is mainly involved in B-cell activation and maturation, with no significant role in indicating previous infection or protecting tissues. Option D, IgM, is the first antibody produced during an acute infection, appearing early in the immune response (within days) and indicating current or recent infection. However, its levels decline rapidly, and it does not persist to mark previous infection or provide long-term tissue protection, unlike IgG.
The CBIC Practice Analysis (2022) and CDC guidelines on serological testing emphasize IgG’s role in assessing past immunity, supported by immunological literature (e.g., Janeway’s Immunobiology, 9th Edition). Thus, IgG is the humoral antibody that best indicates previous infection and assists in protecting tissue, making Option C the correct choice.
References:
* CBIC Practice Analysis, 2022.
* Manual of Clinical Microbiology, ASM Press, 2019.
* Janeway’s Immunobiology, 9th Edition, 2016.
* CDC Serologic Testing Guidelines, 2014.

QUESTION 34
An infection preventionist should collaborate with a public health agency in primary prevention efforts by:

Conducting outbreak investigations.

Performing surveillance for tuberculosis through tuberculin skin test.

Promoting vaccination of health care workers and patients.

Offering blood and body fluid post-exposure prophylaxis.

Primary prevention focuses on preventing the initial occurrence of disease or injury before it manifests, distinguishing it from secondary (early detection) and tertiary (mitigation of complications) prevention. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes the “Prevention and Control of Infectious Diseases” domain, which includes collaboration with public health agencies to implement preventive strategies, aligning with the Centers for Disease Control and Prevention (CDC) framework for infection prevention. The question requires identifying the activity that best fits primary prevention efforts.
Option C, “Promoting vaccination of health care workers and patients,” is the correct answer. Vaccination is a cornerstone of primary prevention, as it prevents the onset of vaccine-preventable diseases (e.g., influenza, hepatitis B, measles) by inducing immunity before exposure. The CDC’s “Immunization of Health-Care Personnel” (2011) and “General Recommendations on Immunization” (2021) highlight the role of vaccination in protecting both healthcare workers and patients, reducing community transmission and healthcare- associated infections. Collaboration with public health agencies, which often oversee vaccination campaigns and supply distribution, enhances this effort, making it a proactive primary prevention strategy.
Option A, “Conducting outbreak investigations,” is a secondary prevention activity. Outbreak investigations occur after cases are identified to control spread and mitigate impact, focusing on containment rather than preventing initial disease occurrence. The CDC’s “Principles of Epidemiology in Public Health Practice” (3rd Edition, 2012) classifies this as a response to an existing problem. Option B, “Performing surveillance for tuberculosis through tuberculin skin test,” is also secondary prevention. Surveillance, including tuberculin skin testing, aims to detect latent or active tuberculosis early to prevent progression or transmission, not to prevent initial infection. The CDC’s “Guidelines for Preventing the Transmission of Mycobacterium tuberculosis” (2005) supports this as a screening tool. Option D, “Offering blood and body fluid post- exposure prophylaxis,” is tertiary prevention. Post-exposure prophylaxis (e.g., for HIV or hepatitis B) is administered after potential exposure to prevent disease development, focusing on mitigating consequences rather than preventing initial exposure, as outlined in the CDC’s “Updated U.S. Public Health Service Guidelines” (2013).
The CBIC Practice Analysis (2022) and CDC guidelines prioritize vaccination as a primary prevention strategy, and collaboration with public health agencies amplifies its reach. Option C best reflects this preventive focus, making it the correct choice.
References:
* CBIC Practice Analysis, 2022.
* CDC Immunization of Health-Care Personnel, 2011.
* CDC General Recommendations on Immunization, 2021.
* CDC Principles of Epidemiology in Public Health Practice, 3rd Edition, 2012.

QUESTION 35
Which of the following is an example of an outcome measure?

Hand hygiene compliance rate

Adherence to Environmental Cleaning

Rate of multi-drug resistant organisms acquisition

Timing of preoperative antibiotic administration

The correct answer is C, “Rate of multi-drug resistant organisms acquisition,” as it represents an example of an outcome measure. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, outcome measures are indicators that reflect the impact or result of infection prevention and control interventions on patient health outcomes or the incidence of healthcare-associated infections (HAIs).
The rate of multi-drug resistant organisms (MDRO) acquisition directly measures the incidence of new infections caused by resistant pathogens, which is a key outcome affected by the effectiveness of infection control practices (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 – Evaluate the effectiveness of infection prevention and control interventions).
Option A (hand hygiene compliance rate) is an example of a process measure, which tracks adherence to specific protocols or practices intended to prevent infections, rather than the resulting health outcome. Option B (adherence to environmental cleaning) is also a process measure, focusing on the implementation of cleaning protocols rather than the end result, such as reduced infection rates. Option D (timing of preoperative antibiotic administration) is another process measure, assessing the timeliness of an intervention to prevent surgical site infections, but it does not directly indicate the outcome (e.g., infection rate) of that intervention.
Outcome measures, such as the rate of MDRO acquisition, are critical for evaluating the success of infection prevention programs and are often used to guide quality improvement initiatives. This aligns with CBIC’s emphasis on using surveillance data to assess the effectiveness of interventions and inform decision-making (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies). The focus on MDRO acquisition specifically highlights a significant healthcare challenge, making it a prioritized outcome measure in infection control.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competencies 2.4 – Evaluate the effectiveness of infection prevention and control interventions, 2.5 – Use data to guide infection prevention and control strategies.

QUESTION 36
Infection Prevention and Control identified a cluster of Aspergillus fumigatus infections in the transplant unit.
The infection preventionist (IP) meets with the unit director and Environmental Services director to begin investigation. What information does the IP need from the Environmental Services director?

Date of last terminal clean of the infected patient rooms

Hospital grade disinfectant used on the transplant unit

Use of dust mitigating strategies during floor care

Date of the last cleaning of the fish tank in the waiting room

The correct answer is A, “Date of last terminal clean of the infected patient rooms,” as this is the most critical information the infection preventionist (IP) needs from the Environmental Services director to begin the investigation of a cluster of Aspergillus fumigatus infections in the transplant unit. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, Aspergillus fumigatus is an environmental fungus that thrives in areas with poor ventilation, construction dust, or inadequate cleaning, posing a significant risk to immunocompromised patients, such as those in transplant units. A terminal clean- thorough disinfection and cleaning of a patient room after discharge or transfer-is a key infection control measure to eliminate fungal spores and other pathogens (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 – Implement environmental cleaning and disinfection protocols).
Determining the date of the last terminal clean helps the IP assess whether lapses in cleaning schedules or procedures could have contributed to the cluster, guiding further environmental sampling or process improvements.
Option B (hospital grade disinfectant used on the transplant unit) is relevant to the investigation but is secondary; the IP would need to know the cleaning schedule first to contextualize the disinfectant’s effectiveness. Option C (use of dust mitigating strategies during floor care) is important, as Aspergillus spores can be aerosolized during floor maintenance, but this is a specific procedural detail that follows the initial focus on cleaning history. Option D (date of the last cleaning of the fish tank in the waiting room) is unlikely to be a priority unless evidence suggests a direct link to the transplant unit, which is not indicated here; Aspergillus is more commonly associated with air quality and room cleaning rather than fish tanks.
The focus on the date of the last terminal clean aligns with CBIC’s emphasis on investigating environmental factors in healthcare-associated infection (HAI) clusters, enabling the IP to collaborate with Environmental Services to pinpoint potential sources and implement corrective actions (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.2 – Analyze surveillance data). This step is foundational to controlling the outbreak and protecting vulnerable patients.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.2 – Analyze surveillance data; Domain III: Infection Prevention and Control, Competency 3.4 – Implement environmental cleaning and disinfection protocols.

QUESTION 37
Which of the following operating suite design features is LEAST important for the prevention of infection?

Type of floor material

Positive pressure air handling

Placement of sinks for surgical scrubs

Control of traffic and traffic flow patterns

The correct answer is A, “Type of floor material,” as it is the least important operating suite design feature for the prevention of infection compared to the other options. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the design of operating suites plays a critical role in infection prevention, particularly for surgical site infections (SSIs). While the type of floor material (e.g., vinyl, tile, or epoxy) can affect ease of cleaning and durability, its impact on infection prevention is secondary to other design elements that directly influence air quality, hygiene practices, and personnel movement (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 – Evaluate the environment for infection risks). Modern flooring materials are generally designed to be non-porous and easily disinfected, mitigating their role as a primary infection risk factor when proper cleaning protocols are followed.
Option B (positive pressure air handling) is highly important because it prevents the influx of contaminated air into the operating suite, reducing the risk of airborne pathogens, including those causing SSIs. This is a standard feature in operating rooms to maintain a sterile environment (AORN Guidelines for Perioperative Practice, 2023). Option C (placement of sinks for surgical scrubs) is critical for ensuring that surgical staff can perform effective hand and forearm antisepsis, a key step in preventing SSIs by reducing microbial load before surgery. Option D (control of traffic and traffic flow patterns) is essential to minimize the introduction of contaminants from outside the operating suite, as excessive or uncontrolled movement can increase the risk of airborne and contact transmission (CDC Guidelines for Environmental Infection Control in Healthcare Facilities, 2019).
The relative unimportance of floor material type stems from the fact that infection prevention relies more on consistent cleaning practices and the aforementioned design features, which directly address pathogen transmission routes. This aligns with CBIC’s focus on evaluating environmental risks based on their direct impact on infection control (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 – Implement environmental cleaning and disinfection protocols).
References: CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competencies 3.4 – Implement environmental cleaning and disinfection protocols, 3.5 – Evaluate the environment for infection risks. AORN Guidelines for Perioperative Practice, 2023. CDC Guidelines for Environmental Infection Control in Healthcare Facilities, 2019.

QUESTION 38
An infection preventionist is evaluating a new catheter that may decrease the rate of catheter-associated urinary tract infections. Which of the following provides the BEST information to support the selection of this catheter?

Staff member preference and product availability

Product materials and vendor information

Value analysis and information provided by the manufacturer

Cost benefit analysis and safety considerations

The correct answer is D, “Cost benefit analysis and safety considerations,” as this provides the best information to support the selection of a new catheter aimed at decreasing the rate of catheter-associated urinary tract infections (CAUTIs). According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, selecting medical devices like catheters for infection prevention involves a comprehensive evaluation that balances efficacy, safety, and economic impact. A cost-benefit analysis assesses the financial implications (e.g., reduced infection rates leading to lower treatment costs) against the cost of the new catheter, while safety considerations ensure the device minimizes patient risk, such as reducing biofilm formation or irritation that contributes to CAUTIs (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 – Ensure safe reprocessing of medical equipment). This dual focus provides evidence-based data to justify the catheter’s adoption, aligning with the goal of improving patient outcomes and reducing healthcare-associated infections (HAIs).
Option A (staff member preference and product availability) is subjective and logistical rather than evidence- based, making it insufficient for a decision that impacts infection rates. Option B (product materials and vendor information) offers technical details but lacks the broader context of efficacy and cost-effectiveness needed for a comprehensive evaluation. Option C (value analysis and information provided by the manufacturer) includes a structured assessment of value, but it may be biased toward the manufacturer’s claims and lacks the independent safety and cost-benefit perspective critical for infection prevention decisions.
The emphasis on cost-benefit analysis and safety considerations reflects CBIC’s priority on using data-driven and patient-centered approaches to select interventions that enhance infection control (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies). This approach ensures the catheter’s selection is supported by robust evidence, optimizing both clinical and economic outcomes in the prevention of CAUTIs.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies; Domain III: Infection Prevention and Control, Competency 3.3 – Ensure safe reprocessing of medical equipment.

QUESTION 39
The Environmental Services department is purchasing a new disinfectant that is an approved hospital disinfectant with no tuberculocidal claim. This product is appropriate for cleaning which of the following items?

Laryngoscope blades

Blood pressure cuff

Respiratory therapy equipment

Ultrasound probe

QUESTION 40
An infection preventionist is utilizing the Shewhart/Deming cycle in an infection control program performance improvement project. In which of the following steps are the results of the interventions compared with the original goal?

Act

Plan

Study

The correct answer is D, “Study,” as this is the step in the Shewhart/Deming cycle (commonly known as the Plan-Do-Study-Act [PDSA] cycle) where the results of the interventions are compared with the original goal.
According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the PDSA cycle is a systematic approach to quality improvement, widely used in infection control programs to test and refine interventions. The cycle consists of four stages: Plan (designing the intervention and setting goals), Do (implementing the intervention on a small scale), Study (analyzing the data and comparing outcomes against the original goal), and Act (standardizing successful changes or adjusting based on findings) (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.2 – Evaluate the effectiveness of educational programs). The Study phase is critical for assessing whether the intervention achieved the intended reduction in infection rates or other performance metrics, providing evidence to guide the next steps.
Option A (Do) involves the execution of the planned intervention, focusing on implementation rather than evaluation, so it does not include comparing results. Option B (Act) is the final step where successful interventions are implemented on a broader scale or adjustments are made, but it follows the comparison made in the Study phase. Option C (Plan) is the initial stage of setting objectives and designing the intervention, which occurs before any results are available for comparison.
The emphasis on the Study phase aligns with CBIC’s focus on using data to evaluate the effectiveness of infection prevention strategies, ensuring that performance improvement projects are evidence-based and goal- oriented (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 – Evaluate the effectiveness of infection prevention and control interventions). This step enables the infection preventionist to determine if the original goal-such as reducing healthcare-associated infections-was met, facilitating continuous improvement.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.4 – Evaluate the effectiveness of infection prevention and control interventions; Domain IV:
Education and Research, Competency 4.2 – Evaluate the effectiveness of educational programs.

QUESTION 41
Working with public health agencies to collect and analyze indicators that might signal an increase in community illness is an example of which type of surveillance?

Passive

Active

Syndromic

Targeted

Surveillance is a critical tool in infection prevention and control, used to monitor disease trends and guide public health responses. The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes the “Surveillance and Epidemiologic Investigation” domain, which aligns with the Centers for Disease Control and Prevention (CDC) “Principles of Epidemiology in Public Health Practice” (3rd Edition, 2012).
The question describes a process of collecting and analyzing indicators to signal an increase in community illness, requiring identification of the appropriate surveillance type among the options provided.
Option C, “Syndromic,” is the correct answer. Syndromic surveillance involves monitoring non-specific health indicators or symptoms (e.g., fever, respiratory complaints, or gastrointestinal issues) that may precede a formal diagnosis, aiming to detect potential outbreaks or increases in community illness early. The CDC defines syndromic surveillance as the real-time or near-real-time collection, analysis, and interpretation of health-related data to provide actionable information, often in collaboration with public health agencies. This approach uses data from sources like emergency department visits, over-the-counter medication sales, or absenteeism reports to identify trends before laboratory confirmation, making it well-suited to the described scenario of signaling community illness increases.
Option A, “Passive,” involves healthcare providers or laboratories reporting cases to public health authorities on a voluntary or mandatory basis without active prompting (e.g., routine notifiable disease reporting). While passive surveillance contributes to baseline data, it is less proactive and not specifically designed to signal early increases in illness, making it less fitting. Option B, “Active,” entails public health officials actively seeking data from healthcare facilities or providers (e.g., calling to confirm cases during an outbreak). This is more resource-intensive and typically used for specific investigations rather than ongoing community trend monitoring, which aligns better with syndromic methods. Option D, “Targeted,” refers to surveillance focused on a specific population, disease, or event (e.g., monitoring TB in a high-risk group). The scenario’s broad focus on community illness indicators does not suggest a targeted approach.
The CBIC Practice Analysis (2022) and CDC guidelines highlight syndromic surveillance as a key strategy for early detection of community-wide health threats, often involving collaboration with public health agencies. Option C best matches the described activity of analyzing indicators to signal illness increases, making it the correct choice.
References:
* CBIC Practice Analysis, 2022.
* CDC Principles of Epidemiology in Public Health Practice, 3rd Edition, 2012.
* CDC Syndromic Surveillance Systems, 2020.

QUESTION 42
What should an infection preventionist prioritize when designing education programs?

Marketing research

Departmental budgets

Prior healthcare experiences

Learning and behavioral science theories

The correct answer is D, “Learning and behavioral science theories,” as this is what an infection preventionist (IP) should prioritize when designing education programs. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, effective education programs in infection prevention and control are grounded in evidence-based learning theories and behavioral science principles. These theories, such as adult learning theory (andragogy), social learning theory, and the health belief model, provide a framework for understanding how individuals acquire knowledge, develop skills, and adopt behaviors (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.1 – Develop and implement educational programs). Prioritizing these theories ensures that educational content is tailored to the learners’ needs, enhances engagement, and promotes sustained behavior change-such as adherence to hand hygiene or proper use of personal protective equipment (PPE)-which are critical for reducing healthcare-associated infections (HAIs).
Option A (marketing research) is more relevant to commercial strategies and audience targeting outside the healthcare education context, making it less applicable to the IP’s role in designing clinical education programs. Option B (departmental budgets) is an important logistical consideration for resource allocation, but it is secondary to the design process; financial constraints should influence implementation rather than the foundational design based on learning principles. Option C (prior healthcare experiences) can inform the customization of content by identifying learners’ backgrounds, but it is not the primary priority; it should be assessed within the context of applying learning and behavioral theories to address those experiences effectively.
The focus on learning and behavioral science theories aligns with CBIC’s emphasis on developing and evaluating educational programs that drive measurable improvements in infection control practices (CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competency 4.2 – Evaluate the effectiveness of educational programs). By prioritizing these theories, the IP can create programs that are scientifically sound, learner-centered, and impactful, ultimately enhancing patient and staff safety.
References: CBIC Practice Analysis, 2022, Domain IV: Education and Research, Competencies 4.1 – Develop and implement educational programs, 4.2 – Evaluate the effectiveness of educational programs.

QUESTION 43
Given the formula for calculating incidence rates, the Y represents which of the following?

Population served

Number of infected patients

Population at risk

Number of events

Incidence rate is a fundamental epidemiological measure used to quantify the frequency of new cases of a disease within a specified population over a defined time period. The Certification Board of Infection Control and Epidemiology (CBIC) supports the use of such metrics in the “Surveillance and Epidemiologic Investigation” domain, aligning with the Centers for Disease Control and Prevention (CDC) “Principles of Epidemiology in Public Health Practice” (3rd Edition, 2012). The formula provided, XY×K=Rate\frac{X}
{Y} \times K = RateYX×K=Rate, represents the standard incidence rate calculation, where KKK is a constant (e.g., 1,000 or 100,000) to express the rate per unit population, and the question asks what YYY represents among the given options.
In the incidence rate formula, XXX typically represents the number of new cases (or events) of the disease occurring during a specific period, and YYY represents the population at risk during that same period. The ratio XY\frac{X}{Y}YX yields the rate per unit of population, which is then multiplied by KKK to standardize the rate (e.g., cases per 1,000 persons). The CDC defines the denominator (YYY) as the population at risk, which includes individuals susceptible to the disease over the observation period. Option B (“Number of infected patients”) might suggest XXX if it specified new cases, but as the denominator YYY, it is incorrect because incidence focuses on new cases relative to the at-risk population, not the total number of infected individuals (which could include prevalent cases). Option C (“Population at risk”) correctly aligns with YYY, representing the base population over which the rate is calculated.
Option A, “Population served,” is a broader term that might include the total population under care (e.g., in a healthcare facility), but it is not specific to those at risk for new infections, making it less precise. Option D,
“Number of events,” could align with XXX (new cases or events), but as the denominator YYY, it does not fit the formula’s structure. The CBIC Practice Analysis (2022) and CDC guidelines reinforce that the denominator in incidence rates is the population at risk, ensuring accurate measurement of new disease occurrence.
References:
* CBIC Practice Analysis, 2022.
* CDC Principles of Epidemiology in Public Health Practice, 3rd Edition, 2012.

QUESTION 44
When evaluating environmental cleaning and disinfectant products as a part of the product evaluation committee, which of the following is responsible for providing information regarding clinical trials?

Infection Preventionist

Clinical representatives

Environmental Services

Manufacturer representatives

The correct answer is D, “Manufacturer representatives,” as they are responsible for providing information regarding clinical trials when evaluating environmental cleaning and disinfectant products as part of the product evaluation committee. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, manufacturers are the primary source of data on the efficacy, safety, and performance of their products, including clinical trial results that demonstrate the disinfectant’s ability to reduce microbial load or prevent healthcare-associated infections (HAIs) (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.4 – Implement environmental cleaning and disinfection protocols).
This information is critical for the committee to assess whether the product meets regulatory standards (e.g., EPA registration) and aligns with infection prevention goals, and it is typically supported by documentation such as peer-reviewed studies or trial data provided by the manufacturer.
Option A (Infection Preventionist) plays a key role in evaluating the product’s fit within infection control practices and may contribute expertise or conduct internal assessments, but they are not responsible for providing clinical trial data, which originates from the manufacturer. Option B (Clinical representatives) can offer insights into clinical usage and outcomes but rely on manufacturer data for trial evidence rather than generating it. Option C (Environmental Services) focuses on the practical application and cleaning processes but lacks the authority or resources to conduct or provide clinical trial information.
The reliance on manufacturer representatives aligns with CBIC’s emphasis on evidence-based decision- making in product selection, ensuring that the product evaluation committee bases its choices on robust, manufacturer-supplied clinical data (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies).
This approach supports the safe and effective implementation of environmental cleaning products in healthcare settings.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies; Domain III: Infection Prevention and Control, Competency 3.4 – Implement environmental cleaning and disinfection protocols.

QUESTION 45
Which statistical test is MOST appropriate for comparing infection rates before and after an intervention?

Student’s t-test

Chi-square test for proportions

Linear regression analysis

Wilcoxon rank-sum test

QUESTION 46
Occupational Health contacts the Infection Preventionist (IP) regarding exposure of a patient to an employee’s blood during surgery. The employee is negative for bloodborne pathogens. What is theNEXT step regarding informing the patient of the exposure?

Disclose the exposure to the patient’s surgeon and allow surgeon to determine if patient should be informed

Disclose the exposure to the patient with the information that the staff member is negative for all bloodborne pathogens

Since this was a solid needle and not a hollow bore needed, follow up is not required or need to be disclosed

The patient does not need to be informed since the employee is negative for all bloodborne pathogens

QUESTION 47
The annual report for Infection Prevention shows a dramatic decrease in urinary catheter days, a decrease in the catheter utilization ratio, and a slight decrease in the number of catheter-associated urinary tract infections (CAUTIs). The report does not show an increase in the overall rate of CAUTI. How would the infection preventionist explain this to the administration?

The rate is incorrect and needs to be recalculated.

The rate may be higher if the denominator is very small.

The rate is not affected by the number of catheter days.

Decreasing catheter days will not have an effect on decreasing CAUTI.

The correct answer is B, “The rate may be higher if the denominator is very small,” as this provides the most plausible explanation for the observed data in the annual report. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the CAUTI rate is calculated as the number of CAUTIs per 1,000 catheter days, where catheter days serve as the denominator. The report indicates a dramatic decrease in urinary catheter days and a slight decrease in the number of CAUTIs, yet the overall CAUTI rate has not increased. This discrepancy can occur if the denominator (catheter days) becomes very small, which can inflate or destabilize the rate, potentially masking an actual increase in the infection risk per catheter day (CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competency 2.2 – Analyze surveillance data). A smaller denominator amplifies the impact of even a slight change in the number of infections, suggesting that the rate may be higher than expected or less reliable, necessitating further investigation.
Option A (the rate is incorrect and needs to be recalculated) assumes an error in the calculation without evidence, which is less specific than the denominator effect explanation. Option C (the rate is not affected by the number of catheter days) is incorrect because the CAUTI rate is directly influenced by the number of catheter days as the denominator; a decrease in catheter days should typically lower the rate if infections decrease proportionally, but the lack of an increase here suggests a calculation or interpretation issue. Option D (decreasing catheter days will not have an effect on decreasing CAUTI) contradicts evidence-based practice, as reducing catheter days is a proven strategy to lower CAUTI incidence, though the rate’s stability here indicates a potential statistical artifact.
The explanation focusing on the denominator aligns with CBIC’s emphasis on accurate surveillance and data analysis to guide infection prevention strategies, allowing the infection preventionist to advise administration on the need to review data trends or adjust monitoring methods (CBIC Practice Analysis, 2022, Domain II:
Surveillance and Epidemiologic Investigation, Competency 2.5 – Use data to guide infection prevention and control strategies). This insight can prompt a deeper analysis to ensure the CAUTI rate reflects true infection risk.
References: CBIC Practice Analysis, 2022, Domain II: Surveillance and Epidemiologic Investigation, Competencies 2.2 – Analyze surveillance data, 2.5 – Use data to guide infection prevention and control strategies.

QUESTION 48
The MOST important characteristic to include when using a template for a comprehensive annual risk assessment is

system strategic goals and objectives.

cost savings attributed to the infection prevention and control program.

facility specific demographics end healthcare-associated Infection data

statewide communicable disease and healthcare-associated infection data

QUESTION 49
A healthcare professional in a clinical microbiology laboratory is concerned about routine exposure to Neisseria meningitidis in culture. The healthcare professional last received the Meningococcal vaccine 8 years ago. What recommendation should be given to the healthcare professional regarding their meningococcal vaccination?

They are due for a booster as it has been over 5 years.

They are due for a booster as it has been over 7 years.

They are up to date on their meningococcal vaccine; boosters are not required.

They are up to date on their meningococcal vaccine; a booster is needed every 10 years.

The correct answer is B, “They are due for a booster as it has been over 7 years,” as this is the appropriate recommendation for the healthcare professional regarding their meningococcal vaccination. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which align with recommendations from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), healthcare professionals with routine exposure to Neisseria meningitidis, such as those in clinical microbiology laboratories, are at increased risk of meningococcal disease due to potential aerosol or droplet exposure during culture handling. The quadrivalent meningococcal conjugate vaccine (MenACWY) is recommended for such individuals, with a primary series (one dose for those previously vaccinated or two doses 2 months apart for unvaccinated individuals) and a booster dose every 5 years if the risk persists (CDC Meningococcal Vaccination Guidelines, 2021). However, for laboratory workers with ongoing exposure, the ACIP specifies a booster interval of every 5 years from the last dose, but this is often interpreted in practice as aligning with the 5-7 year range depending on risk assessment and institutional policy. Since the healthcare professional received the vaccine 8 years ago and works in a high- risk setting, a booster is due, with the 7-year threshold being a practical midpoint for this scenario (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 – Implement measures to prevent transmission of infectious agents).
Option A (they are due for a booster as it has been over 5 years) is close but slightly premature based on the 8- year interval, though it reflects the general 5-year booster guideline for high-risk groups; the 7-year option better matches the specific timeframe. Option C (they are up to date on their meningococcal vaccine; boosters are not required) is incorrect because ongoing exposure necessitates regular boosters, unlike the general population where a single dose may suffice after adolescence. Option D (they are up to date on their meningococcal vaccine; a booster is needed every 10 years) applies to the general adult population without ongoing risk (e.g., post-adolescence vaccination), not to laboratory workers with continuous exposure, where the interval is shorter.
The recommendation for a booster aligns with CBIC’s emphasis on protecting healthcare personnel from occupational exposure to communicable diseases, ensuring compliance with evidence-based immunization practices (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 – Collaborate with organizational leaders). This supports the prevention of meningococcal disease outbreaks in healthcare settings.
References: CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competencies 3.1 – Collaborate with organizational leaders, 3.2 – Implement measures to prevent transmission of infectious agents. CDC Meningococcal Vaccination Guidelines, 2021. ACIP Recommendations for Meningococcal Vaccines, 2020 (updated 2023).

QUESTION 50
There are four cases of ventilator-associated pneumonia in a surgical intensive care unit with a total of 200 ventilator days and a census of 12 patients. Which of the following BEST expresses how this should be reported?

Ventilator-associated pneumonia rate of 2%

20 ventilator-associated pneumonia cases/1000 ventilator days

Postoperative pneumonia rate of 6% in SICU patients

More information is needed regarding ventilator days per patient